Faeth Therapeutics (Nasdaq: FTH) granted three new employees options to purchase 68,000 common shares, effective November 4, 2026.
The awards were employment inducements under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $19.99 per share, equal to the stock’s closing price on the grant date. Each award vests 25% on the first anniversary of the employee’s start date, with the remainder vesting in 36 substantially equal monthly installments, subject to continued service through each vesting date. The options have a ten-year term from the grant date.
Faeth Therapeutics (Nasdaq: FTH) reported a third-quarter 2026 net loss of $20.4 million and updated its PIKTOR cancer development programs. The loss widened from $4.6 million a year earlier, while basic and diluted loss per share narrowed to $0.79 from $3.62. Research and development expenses rose to $11.7 million from $2.5 million; general and administrative expenses increased to $10.4 million from $2.3 million. Cash, cash equivalents and marketable securities totaled $174.8 million at September 30, versus $21.2 million at December 31, 2025.
The FDA granted Fast Track designation to PIKTOR plus paclitaxel for biomarker-selected advanced or recurrent endometrial cancer. Faeth expects Phase 2 PIK-201 topline results by year-end 2026 and initial PIK-101 breast cancer safety and efficacy data in 2027. Preclinical breast cancer models showed suppression of PAM pathway signaling, including AKT.
Faeth Therapeutics (FTH) appointed Adam Schayowitz, executive vice president and head of research and development at Zymeworks, to its board of directors.
Schayowitz brings nearly 20 years of oncology drug development experience, including leadership roles at Pfizer Oncology and Tesaro. He has led dozens of global development programs, including multiple registration programs that resulted in regulatory approvals. Faeth is evaluating its lead program, PIKTOR, in a Phase 1b/2 breast cancer trial and is also advancing it in endometrial cancer.
Faeth Therapeutics (FTH) presented preclinical breast cancer data at ESMO comparing its oral PIKTOR regimen with intravenous gedatolisib.
In mice carrying human HR+/HER2- breast tumors, PIKTOR produced comparable tumor growth inhibition in the PIK3CA-mutated MCF7 model and greater inhibition in the non-mutated HCC1428 model. Combined with fulvestrant and palbociclib, PIKTOR halted tumor growth in HCC1428 and shrank tumors in MCF7. In cell lysates, it reduced AKT enzyme activity to ~10% of uninhibited levels, a deeper reduction than other PI3K and/or mTOR inhibitors tested.
The combination is being tested in the ongoing Phase 1b/2 FTH-PIK-101 trial. Faeth expects interim breast cancer data in 2027 and Phase 2 FTH-PIK-201 topline data in second-line advanced endometrial cancer by year-end 2026. The presented findings are from preclinical models, not patient outcomes.
Faeth Therapeutics (FTH) granted new employees options to purchase an aggregate of 17,000 common shares as employment inducements. The awards cover three employees and were effective October 19, 2026, under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The $19.44 per-share exercise price equals the stock’s closing price on the grant date. Each award vests 25% on the first anniversary of the employee’s start date, with the remainder vesting in 36 substantially equal monthly installments, subject to continued service through each vesting date. The options have a ten-year term from the grant date.
Faeth Therapeutics (Nasdaq: FTH) will present preclinical PIKTOR breast cancer data at ESMO in Madrid on October 23, 2026.
The poster evaluates PIKTOR alone and with fulvestrant, oral selective estrogen receptor degraders (SERDs), and CDK inhibitors in HR+/HER2- breast cancer models. Cellular assays showed suppression of signaling nodes in the PI3K-AKT-mTOR pathway, including AKT, at rates comparable to or exceeding those observed with tested single-node inhibitors. The poster also includes head-to-head comparisons with gedatolisib in two mouse breast cancer xenograft models; comparative outcomes were not disclosed. Faeth intends the preclinical data to inform ongoing development in its FTH-PIK-101 Phase 1b/2 trial. The poster session runs from 15:15 to 16:00 CEST, with the poster available on Faeth’s investor website at the session’s start.
Faeth Therapeutics (FTH) appointed renowned cancer biologist and company scientific co‑founder Karen Vousden, Ph.D., to its Board of Directors, effective September 11, 2026, as the company approaches topline Phase 2 data for its all‑oral PIKTOR program in endometrial cancer.
Vousden is noted for work on the p53 tumor suppressor and tumor metabolic dependencies, and has led research organizations including the Francis Crick Institute and Cancer Research UK’s Beatson Institute. She has served on the board of Bristol Myers Squibb since 2018 and holds fellowships in multiple major scientific academies. Vousden described PIKTOR’s multi‑node inhibition of the PI3K/AKT/mTOR pathway as a rational approach and said she is delighted to join the board.
Faeth Therapeutics (FTH) will host a virtual KOL event on October 6, 2026 to discuss endometrial cancer.
The 10:00 AM ET webcast will feature Marcus Goncalves, MD, PhD, and company management reviewing the PAM (PI3K/AKT/mTOR) pathway, Faeth’s investigational multi-node inhibitor PIKTOR, and its ongoing Phase 2 endometrial cancer trial. Topics include comparison with single-node inhibition, rationale for PIKTOR’s current dose and schedule, prior Phase 1b clinical data, and the unmet need after checkpoint inhibitors. Topline Phase 2 data are anticipated by year-end, followed by a live Q&A session.
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node cancer therapies including lead program PIKTOR, announced management’s participation in multiple September 2026 investor conferences.
Events include Wells Fargo, Citi, Cantor, Morgan Stanley, Baird, H.C. Wainwright, and Deutsche Bank conferences across Boston and New York, featuring fireside chats, 1x1 meetings, and webcasts.
Faeth Therapeutics (Nasdaq: FTH) reported that its Board’s Compensation Committee granted stock options to three new employees for an aggregate of 94,000 shares of common stock, effective August 25, 2026, as inducement awards under the company’s 2026 Inducement Plan and in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $34.52 per share, equal to Faeth’s closing share price on the grant date. According to the company, 25% of each award vests on the employee’s first service anniversary, with the remaining shares vesting in 36 substantially equal monthly installments, subject to continued service. The options have a 10-year term and are governed by the 2026 Inducement Plan and applicable award agreements.